The first ones are the FDA approved EGFR tyrosine kinase inhibitors (e.g., erlotinib and gefitinib), which show high response rates in patients with NSCLC harbouring EGFR mutations [90,91]. Here, EGFR is linked to non-small cell lung carcinoma.